Clinical Observation on 35 Cases of Chronic Hepatitis B Complicated with Depression Treated with Changyu Xiaoyao Fang（ 菖郁逍遥方） Combined with Entecavir Dispersible Tablets

CHEN Shaodong; WANG Hongguo; YANG Jia’en; TANG Jinmo; WU Chuncheng; LIANG Huiqing

doi:10.13288/j.11-2166/r.2015.14.012

您当前的位置：

首页 >

文章列表页 >

Clinical Observation on 35 Cases of Chronic Hepatitis B Complicated with Depression Treated with Changyu Xiaoyao Fang（菖郁逍遥方） Combined with Entecavir Dispersible Tablets

更新时间：2021-11-17

- Clinical Observation on 35 Cases of Chronic Hepatitis B Complicated with Depression Treated with Changyu Xiaoyao Fang（菖郁逍遥方） Combined with Entecavir Dispersible Tablets
- Journal of Traditional Chinese Medicine Vol. 56, Issue 14, Pages: 1208-1211(2015)
- 作者机构：
  
  1. 厦门大学医学院
  2. 厦门市中医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2015.14.012
  CLC： R512.62;R749.4
- Published：2015
- 稿件说明：
移动端阅览
[1]陈少东,王宏国,杨嘉恩,唐金模,吴春城,梁惠卿.菖郁逍遥方联合恩替卡韦分散片治疗慢性乙型病毒性肝炎伴抑郁症35例临床观察[J].中医杂志,2015,56(14):1208-1211.

CHEN Shaodong, WANG Hongguo, YANG Jia’en, et al. Clinical Observation on 35 Cases of Chronic Hepatitis B Complicated with Depression Treated with Changyu Xiaoyao Fang（菖郁逍遥方） Combined with Entecavir Dispersible Tablets[J]. Journal of Traditional Chinese Medicine2015, 56(14): 1208-1211.
[1]陈少东,王宏国,杨嘉恩,唐金模,吴春城,梁惠卿.菖郁逍遥方联合恩替卡韦分散片治疗慢性乙型病毒性肝炎伴抑郁症35例临床观察[J].中医杂志,2015,56(14):1208-1211. DOI： 10.13288/j.11-2166/r.2015.14.012.

CHEN Shaodong, WANG Hongguo, YANG Jia’en, et al. Clinical Observation on 35 Cases of Chronic Hepatitis B Complicated with Depression Treated with Changyu Xiaoyao Fang（菖郁逍遥方） Combined with Entecavir Dispersible Tablets[J]. Journal of Traditional Chinese Medicine2015, 56(14): 1208-1211. DOI： 10.13288/j.11-2166/r.2015.14.012.

摘要

目的观察菖郁逍遥方联合恩替卡韦分散片治疗慢性乙型病毒性肝炎伴抑郁症的临床疗效及可能的作用机制。方法 67例慢性乙型病毒性肝炎伴抑郁症患者随机分为治疗组35例、对照组32例。在口服恩替卡韦分散片每日0.5 mg的基础上

对照组加服氟哌噻吨美利曲辛片

每日2次

每次1片;治疗组加服中药复方菖郁逍遥方

每日1剂

两组疗程均为8周。治疗前后分别观察两组患者17项汉密尔顿抑郁量表（HAMD）、慢性肝病问卷（CLDQ）积分以及血清白细胞介素6（IL-6）、肿瘤坏死因子α（TNF-α）水平;比较两组患者抑郁状态疗效、血清丙氨酸氨基转移酶（ALT）复常率及乙型肝炎病毒DNA（HBV DNA）阴转率。结果治疗组抑郁状态疗效总有效率、ALT复常率、HBV DNA阴转率分别为80.00%、80.00%、60.00%

对照组分别为65.63%、62.50%、46.88%

治疗组均优于对照组（P<0.05）。与治疗前比较

治疗后两组患者HAMD评分、IL-6、TNF-α水平均降低

CLDQ各项得分及总积分均增加（P<0.05或P<0.01）;治疗后治疗组IL-6、TNF-α水平和CLDQ各项得分及总积分改善程度较对照组更显著（P<0.05）。结论菖郁逍遥方联合恩替卡韦分散片可显著改善慢性乙型病毒性肝炎伴抑郁症患者的抑郁状态

并能增强抗病毒疗效、提高患者生活质量

其作用机制可能与抑制炎症反应相关。

Abstract

Objective To observe the clinical effect and possible mechanism of Changyu Xiaoyao Fang combined with entecavir dispersible tablets in treating chronic hepatitis B accompanied with depression. Methods67 patients with chronic hepatitis B accompanied with depression were randomly divided into a treatment group of 35 cases and a control group of 32 cases. In addition to taking 0. 5 mg of entecavir dispersible tablet orally

control group was given flupentixol（ 0. 5 mg） and melitracen（ 10 mg） tablet

one tablet twice a day orally

and treatment group was given Changyu Xiaoyao Fang one dose a day orally

both for 8 weeks. The scores of Hamilton Depression Scale（ HAMD） and Chronic Liver Disease Questionnaire（ CLDQ）

as well as serum levels of interleukin 6（ IL-6） and Tumor Necrosis Factorα（ TNF-α） were detected before and after treatment. The improvement of depression

the normalization rate of serum level of alanine aminotransferase（ ALT）

and negative conversion rate of Hepatitis B Virus DNA（ HBV DNA） in patients in both groups were observed after treatment. Results After treatment

the total effective rate in depression improvement

the normalization rate of ALT

and the negative conversion rate of HBV DNA was 80. 0%

80. 00% and 60. 00%

respectively in treatment group

65. 6%

62. 50% and 46. 88%

respectively in control group. The effects of all indexes in treatment group were superior to those in control group（ P <0. 05）. The scores of HAMD

and levels of IL-6 and TNF-αwere decreased

and the scores of every items and total score of CLDQ were increased after treatment（ P < 0. 05 or P < 0. 01）. The improvement of IL-6

TNF-αand the scores of every items and total score of CLDQ in treatment group were superior to those in control group（ P < 0. 05）.Conclusion Changyu Xiaoyao Fang combined with entecavir dispersible tablets could improve depression condition in patients with chronic hepatitis B accompanied with depression

strengthen antiviral effect

and improve quality of life. The mechanism may relate to inhibiting inflammation reaction.

关键词

Keywords

references

查看原文

Views

187

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Comparative Analysis of Clinical Efficacy of Electro-acupuncture and Simple Acupuncture in the Treatment of First-Episode Mild-to-Moderate Depression

Clinical Observation on Jieyu Jiaonang（解郁胶囊） Combined with Paroxetine Treating 50 Depression Cases

Theoretical Basis and Application Prospects of Aromatherapy in Traditional Chinese Medicine for Treating Depression

Traditional Chinese Medicine External Treatment Strategies for Somatic Symptoms of Depression：from the Perspective of the Five Body Constituents

Experience in Treating Depression with the Combined Use of Acupuncture and Herbal Medicine Under the Guiding Principle of Deficiency and Excess

Related Author

HAN Duan

ZHANG Honglin

WANG Xiaoling

SUN Haishu

HUANG Shenghui

CHEN Linqing

LIU Zhijun

LI Xiangli

Related Institution

School of Acupuncture, Moxibustion and Tuina, Beijing University of Chinese Medicine

Guang’ anmen Hospital,China Academy of Chinese Medical Sciences

Institute of Information on Traditional Chinese Medicine,China Academy of Chinese Medical Sciences

北京中医药大学针灸推拿学院中国中医科学院广安门医院中国中医科学院中医药信息研究所

Affiliated Hospital of Gansu University of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰